https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/660655/mfn-deals-lilly-takeout-fda-pick-overton-a-biocentury-podcasthttps://www.biocentury.com/article/660655/mfn-deals-lilly-takeout-fda-pick-overton-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMFN DEALS, LILLY TAKEOUT, FDA PICK OVERTON — A BIOCENTURY PODCASTMonday’s drug pricing reveal by White House short on U.S. biopharmasMon, 31 Aug 2026 18:38:55 -0700https://www.biocentury.com/article/660659/white-house-fails-to-bring-mid-tier-biotechs-to-mfn-tablehttps://www.biocentury.com/article/660659/white-house-fails-to-bring-mid-tier-biotechs-to-mfn-table?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWHITE HOUSE FAILS TO BRING MID-TIER BIOTECHS TO MFN TABLEContrary to administration leaks, high-profile mid-sized biotechs were conspicuous by their absence at a White House press conferenceMon, 31 Aug 2026 17:52:50 -0700https://www.biocentury.com/article/660654/lilly-s-deal-spree-continues-with-merida-takeout-deals-reporthttps://www.biocentury.com/article/660654/lilly-s-deal-spree-continues-with-merida-takeout-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSLILLY’S DEAL SPREE CONTINUES WITH MERIDA TAKEOUT: DEALS REPORTHaisco, Duality feature in cross-border deals; and moreMon, 31 Aug 2026 17:17:19 -0700https://www.biocentury.com/article/660638/can-silencers-add-benefit-in-attr-cmhttps://www.biocentury.com/article/660638/can-silencers-add-benefit-in-attr-cm?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTCAN SILENCERS ADD BENEFIT IN ATTR-CM?Detailed data from Phase III CARDIO-TTRansform trial of eplontersen from AZ/Ionis raise more questionsFri, 28 Aug 2026 16:35:05 -0700https://www.biocentury.com/article/660644/mid-sized-biotechs-pressured-to-accept-mfn-deals-crafted-for-big-pharmahttps://www.biocentury.com/article/660644/mid-sized-biotechs-pressured-to-accept-mfn-deals-crafted-for-big-pharma?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMID-SIZED BIOTECHS PRESSURED TO ACCEPT MFN DEALS CRAFTED FOR BIG PHARMAComplex calculus centering on payer mix and tariff exposure underpins decisions to make most-favored nation pricing dealsFri, 28 Aug 2026 16:25:12 -0700https://www.biocentury.com/article/660640/trans-pacific-ausperbio-draws-120m-to-advance-aso-for-chronic-hbv-finance-reporthttps://www.biocentury.com/article/660640/trans-pacific-ausperbio-draws-120m-to-advance-aso-for-chronic-hbv-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCETRANS-PACIFIC AUSPERBIO DRAWS $120M TO ADVANCE ASO FOR CHRONIC HBV: FINANCE REPORTPlus: Population Health, Arch launch Asia-to-West NewCo Sentivera with Haisco program, and moreFri, 28 Aug 2026 16:17:47 -0700https://www.biocentury.com/article/660629/the-global-fih-trials-race-a-back-to-school-podcast-specialhttps://www.biocentury.com/article/660629/the-global-fih-trials-race-a-back-to-school-podcast-special?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE GLOBAL FIH TRIALS RACE, A BACK TO SCHOOL PODCAST SPECIAL Back to School 2026: The bold risks required to overhaul first-in-human studies around the worldThu, 27 Aug 2026 17:06:45 -0700https://www.biocentury.com/article/660560/kynexis-lowering-kynurenic-acid-levels-to-improve-cognitive-functionhttps://www.biocentury.com/article/660560/kynexis-lowering-kynurenic-acid-levels-to-improve-cognitive-function?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEKYNEXIS: LOWERING KYNURENIC ACID LEVELS TO IMPROVE COGNITIVE FUNCTION Dutch biotech’s KAT2 inhibitor for cognitive impairment associated with schizophrenia is backed by nine-figure series AThu, 27 Aug 2026 16:28:54 -0700https://www.biocentury.com/article/660624/at-least-nine-pdufa-dates-on-fda-s-september-dockethttps://www.biocentury.com/article/660624/at-least-nine-pdufa-dates-on-fda-s-september-docket?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEAT LEAST NINE PDUFA DATES ON FDA’S SEPTEMBER DOCKETFour new therapeutics up for orphan indicationsThu, 27 Aug 2026 13:15:05 -0700https://www.biocentury.com/article/660618/revmed-s-first-in-class-pancreatic-therapy-among-fastest-cnpv-approvalshttps://www.biocentury.com/article/660618/revmed-s-first-in-class-pancreatic-therapy-among-fastest-cnpv-approvals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONREVMED’S FIRST-IN-CLASS PANCREATIC THERAPY AMONG FASTEST CNPV APPROVALS Rasonque daraxonrasib is first new cancer drug under FDA’s pilot programWed, 26 Aug 2026 17:02:12 -0700https://www.biocentury.com/article/660615/science-spotlight-microbiome-biomarkers-show-promise-in-gi-cancerhttps://www.biocentury.com/article/660615/science-spotlight-microbiome-biomarkers-show-promise-in-gi-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: MICROBIOME BIOMARKERS SHOW PROMISE IN GI CANCERBioCentury's translational roundup also includes newly identified immune hubs in the skull and a stem cell model of endometriosisWed, 26 Aug 2026 16:01:17 -0700https://www.biocentury.com/article/660401/how-fast-can-first-in-human-trials-move-molnupiravir-set-16-week-benchmarkhttps://www.biocentury.com/article/660401/how-fast-can-first-in-human-trials-move-molnupiravir-set-16-week-benchmark?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONHOW FAST CAN FIRST-IN-HUMAN TRIALS MOVE? MOLNUPIRAVIR SET 16-WEEK BENCHMARKThe COVID-19 program compressed a process estimated to take 46 weeks by eliminating white space across regulatory review, trial start-up and executionWed, 26 Aug 2026 15:37:45 -0700https://www.biocentury.com/article/660613/with-biohaven-deal-sk-biopharma-builds-epilepsy-franchise-takes-step-toward-big-biotechhttps://www.biocentury.com/article/660613/with-biohaven-deal-sk-biopharma-builds-epilepsy-franchise-takes-step-toward-big-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSWITH BIOHAVEN DEAL, SK BIOPHARMA BUILDS EPILEPSY FRANCHISE, TAKES STEP TOWARD ‘BIG BIOTECH’Korean company adds late-stage seizure therapy behind growth product Xcopri, refreshing Biohaven’s balance sheetWed, 26 Aug 2026 12:17:30 -0700https://www.biocentury.com/article/660606/pilkington-departs-hsbc-for-natwest-s-new-venture-teamhttps://www.biocentury.com/article/660606/pilkington-departs-hsbc-for-natwest-s-new-venture-team?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSPILKINGTON DEPARTS HSBC FOR NATWEST’S NEW VENTURE TEAMPlus: Arcutis vet Todd Edwards joins Oruka to lead commercial Tue, 25 Aug 2026 18:02:25 -0700https://www.biocentury.com/article/660603/nyu-physician-scientist-traces-oxygen-metabolism-to-pediatric-disease-breakthroughhttps://www.biocentury.com/article/660603/nyu-physician-scientist-traces-oxygen-metabolism-to-pediatric-disease-breakthrough?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONNYU PHYSICIAN-SCIENTIST TRACES OXYGEN METABOLISM TO PEDIATRIC DISEASE BREAKTHROUGHPacold’s Trailblazer Prize-winning research on hypoxic tumor metabolism yielded a therapy for a rare mitochondrial diseaseTue, 25 Aug 2026 16:52:26 -0700https://www.biocentury.com/article/660488/federated-learning-requires-more-than-big-tech-infrastructurehttps://www.biocentury.com/article/660488/federated-learning-requires-more-than-big-tech-infrastructure?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFEDERATED LEARNING REQUIRES MORE THAN BIG TECH INFRASTRUCTUREAmazon and Nvidia provide essential building blocks, while orchestration layers and workbench integrations turn them into networks R&D can useTue, 25 Aug 2026 13:00:44 -0700https://www.biocentury.com/article/660596/moderna-vaccine-genentech-obesity-deal-trump-s-fda-pick-a-biocentury-podcasthttps://www.biocentury.com/article/660596/moderna-vaccine-genentech-obesity-deal-trump-s-fda-pick-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMODERNA VACCINE, GENENTECH OBESITY DEAL, TRUMP’S FDA PICK — A BIOCENTURY PODCASTA Phase III melanoma win gives Moderna and Merck important validation for mRNA neoantigen vaccines; Genentech partners with Hanmi; Heidi Overton on deck for FDAMon, 24 Aug 2026 18:22:17 -0700https://www.biocentury.com/article/660290/federated-learning-tests-its-limits-in-drug-discoveryhttps://www.biocentury.com/article/660290/federated-learning-tests-its-limits-in-drug-discovery?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFEDERATED LEARNING TESTS ITS LIMITS IN DRUG DISCOVERYNew architectures can learn across heterogeneous proprietary datasets, but scarce Mon, 24 Aug 2026 16:42:39 -0700https://www.biocentury.com/article/660595/roche-adds-hanmi-s-obesity-asset-via-licensing-agreement-deals-reporthttps://www.biocentury.com/article/660595/roche-adds-hanmi-s-obesity-asset-via-licensing-agreement-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSROCHE ADDS HANMI’S OBESITY ASSET VIA LICENSING AGREEMENT: DEALS REPORTPharma pays $190M up front for Ucn2 analog that has begun clinical testing; plus Ambros/Werewolf and moreMon, 24 Aug 2026 16:39:30 -0700https://www.biocentury.com/article/660396/similar-regulatory-clocks-divergent-paths-to-study-starthttps://www.biocentury.com/article/660396/similar-regulatory-clocks-divergent-paths-to-study-start?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTSIMILAR REGULATORY CLOCKS, DIVERGENT PATHS TO STUDY STARTReview structure, dedicated trial units, and site operations together determine how quickly clinical trials reach first patientFri, 21 Aug 2026 14:56:23 -0700https://www.biocentury.com/article/660592/buoyed-by-readout-amylyx-banks-500m-ahead-of-submission-finance-reporthttps://www.biocentury.com/article/660592/buoyed-by-readout-amylyx-banks-500m-ahead-of-submission-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBUOYED BY READOUT, AMYLYX BANKS $500M AHEAD OF SUBMISSION: FINANCE REPORTPlus: Ambros lines up $150M PIPE as it heads to NASDAQ via reverse merger; and moreFri, 21 Aug 2026 13:51:30 -0700https://www.biocentury.com/article/660470/loosening-the-reins-the-bold-risks-required-to-overhaul-first-in-human-trialshttps://www.biocentury.com/article/660470/loosening-the-reins-the-bold-risks-required-to-overhaul-first-in-human-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONLOOSENING THE REINS: THE BOLD RISKS REQUIRED TO OVERHAUL FIRST-IN-HUMAN TRIALS Back to School 2026: China has brought new urgency to a longstanding bottleneck. Transformational reform will require rethinking the risk-control paradigmFri, 21 Aug 2026 13:10:44 -0700https://www.biocentury.com/article/660586/ai-exec-reis-filho-leaves-astrazeneca-for-strategy-role-at-foresite-labshttps://www.biocentury.com/article/660586/ai-exec-reis-filho-leaves-astrazeneca-for-strategy-role-at-foresite-labs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSAI EXEC REIS-FILHO LEAVES ASTRAZENECA FOR STRATEGY ROLE AT FORESITE LABSPlus: New CEOs at Neumora and Juvena; and moreThu, 20 Aug 2026 16:58:33 -0700https://www.biocentury.com/article/660583/mapping-first-steps-toward-scaling-genetic-medicines-c-path-s-romero-on-the-biocentury-showhttps://www.biocentury.com/article/660583/mapping-first-steps-toward-scaling-genetic-medicines-c-path-s-romero-on-the-biocentury-show?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMAPPING FIRST STEPS TOWARD SCALING GENETIC MEDICINES: C-PATH’S ROMERO ON THE BIOCENTURY SHOWOne to Millions will begin with shared ASO safety data,Thu, 20 Aug 2026 16:54:38 -0700https://www.biocentury.com/article/660387/denmark-spain-and-the-u-k-build-fast-lanes-for-fih-trials-back-to-school-2026https://www.biocentury.com/article/660387/denmark-spain-and-the-u-k-build-fast-lanes-for-fih-trials-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONDENMARK, SPAIN, AND THE U.K. BUILD FAST LANES FOR FIH TRIALS — BACK TO SCHOOL 2026National initiatives are pushing review times well below EU-wide targetsThu, 20 Aug 2026 16:23:45 -0700https://www.biocentury.com/article/660310/big-ambitions-big-fractures-europe-s-fih-conundrum-back-to-school-2026https://www.biocentury.com/article/660310/big-ambitions-big-fractures-europe-s-fih-conundrum-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONBIG AMBITIONS, BIG FRACTURES — EUROPE’S FIH CONUNDRUM: BACK TO SCHOOL 2026Can Europe overcome its fractured regulatory environment to be globally competitive?Thu, 20 Aug 2026 15:02:57 -0700https://www.biocentury.com/article/660429/outside-of-china-other-asian-biotech-hubs-have-early-ambitions-toohttps://www.biocentury.com/article/660429/outside-of-china-other-asian-biotech-hubs-have-early-ambitions-too?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONOUTSIDE OF CHINA, OTHER ASIAN BIOTECH HUBS HAVE EARLY AMBITIONS, TOOBack to School 2026: Korea, Taiwan, and Singapore seek earlier roles in global development, while Japan removes barriers to joining global trialsWed, 19 Aug 2026 17:41:07 -0700https://www.biocentury.com/article/660329/australia-looks-beyond-healthy-volunteers-to-defend-phase-i-edge-back-to-school-2026https://www.biocentury.com/article/660329/australia-looks-beyond-healthy-volunteers-to-defend-phase-i-edge-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONAUSTRALIA LOOKS BEYOND HEALTHY VOLUNTEERS TO DEFEND PHASE I EDGE: BACK TO SCHOOL 2026Government and CRO initiatives aim to streamline trial infrastructure and extend early studies into patient cohorts as global competition intensifiesWed, 19 Aug 2026 17:13:12 -0700https://www.biocentury.com/article/660577/moderna-merck-phase-iii-win-opens-door-to-personalized-neoantigen-vaccineshttps://www.biocentury.com/article/660577/moderna-merck-phase-iii-win-opens-door-to-personalized-neoantigen-vaccines?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMODERNA, MERCK PHASE III WIN OPENS DOOR TO PERSONALIZED NEOANTIGEN VACCINESMelanoma adjuvant success could mark a turnaround for ModernaWed, 19 Aug 2026 17:03:33 -0700https://www.biocentury.com/article/660573/pick-of-trump-loyalist-overton-revives-questions-of-fda-independencehttps://www.biocentury.com/article/660573/pick-of-trump-loyalist-overton-revives-questions-of-fda-independence?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWPICK OF TRUMP LOYALIST OVERTON REVIVES QUESTIONS OF FDA INDEPENDENCE Johns Hopkins-trained physician was chief policy officer at Center for a Healthy America before joining White HouseWed, 19 Aug 2026 08:02:03 -0700https://www.biocentury.com/article/660557/science-spotlight-a-late-acting-antimalarial-turns-infection-into-vaccinationhttps://www.biocentury.com/article/660557/science-spotlight-a-late-acting-antimalarial-turns-infection-into-vaccination?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: A LATE-ACTING ANTIMALARIAL TURNS INFECTION INTO VACCINATION BioCentury’s translational roundup also includes research on hypertension, asthma, and brain-penetrant TEAD inhibitorsTue, 18 Aug 2026 17:12:40 -0700https://www.biocentury.com/article/660388/china-s-value-proposition-in-first-in-human-trials-back-to-school-2026https://www.biocentury.com/article/660388/china-s-value-proposition-in-first-in-human-trials-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONCHINA’S VALUE PROPOSITION IN FIRST-IN-HUMAN TRIALS: BACK TO SCHOOL 2026On the edge of the radar just a few years ago, China has moved center stage in FIH trials by continually innovating and modernizing rulesTue, 18 Aug 2026 16:48:51 -0700https://www.biocentury.com/article/660555/aiming-for-larger-rare-disease-market-biomarin-buys-alesta-programhttps://www.biocentury.com/article/660555/aiming-for-larger-rare-disease-market-biomarin-buys-alesta-program?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSAIMING FOR LARGER RARE DISEASE MARKET, BIOMARIN BUYS ALESTA PROGRAMAcquisition-and-spinout deal brings hypophosphatasia program into BioMarin’s skeletal disease portfolioTue, 18 Aug 2026 15:33:05 -0700https://www.biocentury.com/article/660539/summer-s-venture-wave-drugging-beta-catenin-capricor-fdahttps://www.biocentury.com/article/660539/summer-s-venture-wave-drugging-beta-catenin-capricor-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCESUMMER’S VENTURE WAVE; DRUGGING BETA-CATENIN; CAPRICOR & FDA  Thirteen venture rounds last week brought in nearly $800MMon, 17 Aug 2026 18:23:09 -0700https://www.biocentury.com/article/660359/going-beyond-trialblazer-to-speed-fih-trialshttps://www.biocentury.com/article/660359/going-beyond-trialblazer-to-speed-fih-trials?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONGOING BEYOND TRIALBLAZER TO SPEED FIH TRIALSBack to School 2026: Proposals center on emulating Australia, integrating trials into routine careMon, 17 Aug 2026 16:48:15 -0700https://www.biocentury.com/article/660349/u-s-aims-to-slash-pre-ind-timelines-back-to-school-2026https://www.biocentury.com/article/660349/u-s-aims-to-slash-pre-ind-timelines-back-to-school-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONU.S. AIMS TO SLASH PRE-IND TIMELINES: BACK TO SCHOOL 2026Cutting the time needed to file an IND is low-hanging fruitMon, 17 Aug 2026 16:45:07 -0700https://www.biocentury.com/article/660517/pivotal-misses-punish-eyepoint-and-tenaxhttps://www.biocentury.com/article/660517/pivotal-misses-punish-eyepoint-and-tenax?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPIVOTAL MISSES PUNISH EYEPOINT AND TENAXBioCentury’s Clinical Report Aug. 10-17Mon, 17 Aug 2026 14:45:11 -0700https://www.biocentury.com/article/660542/slate-redx-to-reach-nasdaq-via-reverse-mergers-deals-reporthttps://www.biocentury.com/article/660542/slate-redx-to-reach-nasdaq-via-reverse-mergers-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSSLATE, REDX TO REACH NASDAQ VIA REVERSE MERGERS: DEALS REPORTPlus: Bankrupt Sangamo’s assets go to Lilly, PTC; and moreMon, 17 Aug 2026 14:36:11 -0700https://www.biocentury.com/article/660495/will-capricor-s-latest-move-give-deramiocel-new-lifehttps://www.biocentury.com/article/660495/will-capricor-s-latest-move-give-deramiocel-new-life?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEWILL CAPRICOR’S LATEST MOVE GIVE DERAMIOCEL NEW LIFE?Spark for shares still leaves stock a long way from Phase III winFri, 14 Aug 2026 19:03:06 -0700https://www.biocentury.com/article/660460/protuoso-bio-building-mix-and-match-multi-functional-biologicshttps://www.biocentury.com/article/660460/protuoso-bio-building-mix-and-match-multi-functional-biologics?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEPROTUOSO BIO: BUILDING MIX-AND-MATCH MULTI-FUNCTIONAL BIOLOGICSThe hub-and-spoke-structured company combines diverse protein modalities into single molecules for synergistic effects in complex diseasesFri, 14 Aug 2026 18:11:14 -0700https://www.biocentury.com/article/660480/boulevard-homing-in-on-b-cell-biology-in-autoimmunityhttps://www.biocentury.com/article/660480/boulevard-homing-in-on-b-cell-biology-in-autoimmunity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEBOULEVARD: HOMING IN ON B CELL BIOLOGY IN AUTOIMMUNITYDeerfield-incubated Boulevard launched with $65M to develop differentiated B cell-directed therapiesFri, 14 Aug 2026 17:15:34 -0700https://www.biocentury.com/article/660491/syndicate-backs-maplight-illuminating-path-forward-in-schizophrenia-public-equity-reporthttps://www.biocentury.com/article/660491/syndicate-backs-maplight-illuminating-path-forward-in-schizophrenia-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCESYNDICATE BACKS MAPLIGHT, ILLUMINATING PATH FORWARD IN SCHIZOPHRENIA: PUBLIC EQUITY REPORTPlus: Follow-ons for AbCellera and Silence; Vogenx’s IPO; and moreFri, 14 Aug 2026 16:14:43 -0700https://www.biocentury.com/article/660475/khartis-emerges-from-stealth-with-95m-to-challenge-tepezza-venture-reporthttps://www.biocentury.com/article/660475/khartis-emerges-from-stealth-with-95m-to-challenge-tepezza-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKHARTIS EMERGES FROM STEALTH WITH $95M TO CHALLENGE TEPEZZA: VENTURE REPORTPlus: Rounds for Boulevard, Vaderis, Infinimmune, K2 and moreThu, 13 Aug 2026 18:20:10 -0700https://www.biocentury.com/article/660484/global-drugs-that-made-the-grade-in-china-in-2025https://www.biocentury.com/article/660484/global-drugs-that-made-the-grade-in-china-in-2025?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEGLOBAL DRUGS THAT MADE THE GRADE IN CHINA IN 2025NMPA approved 60 drugs and vaccines already marketed abroad, with Merck leading the sponsorsThu, 13 Aug 2026 18:16:42 -0700https://www.biocentury.com/article/660478/vir-cfo-o-byrne-joining-olemahttps://www.biocentury.com/article/660478/vir-cfo-o-byrne-joining-olema?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSVIR CFO O’BYRNE JOINING OLEMAPlus: Changes at Zenas, Kamada and moreThu, 13 Aug 2026 17:12:01 -0700https://www.biocentury.com/article/660458/science-spotlight-regeneron-s-genomics-derived-metabolic-targethttps://www.biocentury.com/article/660458/science-spotlight-regeneron-s-genomics-derived-metabolic-target?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: REGENERON’S GENOMICS-DERIVED METABOLIC TARGETBioCentury’s translational roundup also features AI-designed bacteriophages and a peptide strategy for immunogenic tumor cell deathWed, 12 Aug 2026 17:27:53 -0700https://www.biocentury.com/article/660442/five-approaches-to-drug-cancer-s-undruggable-catenin-pathwayhttps://www.biocentury.com/article/660442/five-approaches-to-drug-cancer-s-undruggable-catenin-pathway?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFIVE APPROACHES TO DRUG CANCER’S ‘UNDRUGGABLE’ Β-CATENIN PATHWAYClinical companies are targeting five different nodes to separate oncogenic signaling from Wnt’s roles in healthy tissueWed, 12 Aug 2026 16:53:50 -0700https://www.biocentury.com/article/660452/coregen-one-gene-knockout-many-solid-tumorshttps://www.biocentury.com/article/660452/coregen-one-gene-knockout-many-solid-tumors?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILECOREGEN: ONE GENE KNOCKOUT, MANY SOLID TUMORSHouston-based company is knocking out a master transcriptional regulator in regulatory T cells to strip solid tumors of their immune cloakWed, 12 Aug 2026 16:31:11 -0700https://www.biocentury.com/article/660447/next-chapter-for-legend-s-huang-comes-atop-k2https://www.biocentury.com/article/660447/next-chapter-for-legend-s-huang-comes-atop-k2?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNEXT CHAPTER FOR LEGEND’S HUANG COMES ATOP K2Plus: C-suite overhaul at Bicara, includes CEO succession plan — and moreTue, 11 Aug 2026 18:30:33 -0700https://www.biocentury.com/article/660412/fda-moving-fast-on-expedited-ind-pilothttps://www.biocentury.com/article/660412/fda-moving-fast-on-expedited-ind-pilot?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA MOVING FAST ON EXPEDITED IND PILOTThird-party reviewers to be selected by year-end, IND submissions to start next yearTue, 11 Aug 2026 16:36:18 -0700